<DOC>
	<DOCNO>NCT00000725</DOCNO>
	<brief_summary>To evaluate safety toxicity combination therapy AIDS-associated Kaposi 's sarcoma zidovudine ( AZT ) two kind interferon alpha . The two kind interferon alpha ( IFN-A ) interferon alpha-2A ( recombinant ) ( IFN-A2A ) . To define pharmacokinetics AZT IFN-A IFN-A2A give combination ; define maximum tolerate dose drug combination define dos use Phase II trial . AZT find inhibit vitro ( test tube ) cell kill effect HIV , interferon ( IFN-A IFN-A2A ) show antiviral antitumor effect Kaposi 's sarcoma . It reasonable assume synergistic effect enhance antitumor response may see combination therapy . A study evaluate safety efficacy AZT combination IFN-A IFN-A2A warrant .</brief_summary>
	<brief_title>A Phase I Study AZT Human Interferon Alpha ( Recombinant Alpha-2A Lymphoblastoid ) Treatment AIDS-Associated Kaposi 's Sarcoma</brief_title>
	<detailed_description>AZT find inhibit vitro ( test tube ) cell kill effect HIV , interferon ( IFN-A IFN-A2A ) show antiviral antitumor effect Kaposi 's sarcoma . It reasonable assume synergistic effect enhance antitumor response may see combination therapy . A study evaluate safety efficacy AZT combination IFN-A IFN-A2A warrant . Patients randomized receive IFN-A IFN-A2A ( give intramuscular injection ) combine AZT ( take orally ) daily 8 week . Study stop maximum tolerate dose ( MTD ) reach . Two cohort 4 patient enter dose level . Patients enter next dose level patient complete 3 week treatment . AZT escalate unacceptable toxicity ( grade 2 = &gt; 3 patient &gt; grade 2 patient ) , subsequent increase IFN-A IFN-A2A permit , AZT dose remain fixed . The MTD give IFN-A IFN-A2A dose level define grade 2 toxicity ( grade 3 hemoglobin , neutrophil count , SGOT ) 4 6 patient . Patients blood draw every week general health evaluate . Pharmacokinetic study do day 1 , 21 , 24 . Patients tolerate combination may continue dose level 1 year except patient reach complete remission = &gt; 90 day , IFN-A IFN-A2A decrease 3 time week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients must biopsyproven AIDSassociated Kaposi 's sarcoma . Evidence HIV infection manifest positive antibody test . Exclusion Criteria Active drug alcohol abuse . Coexisting Condition : Excluded patient : Active opportunistic infection require ongoing therapy . Excluded within 90 day study entry : Must therapy Pneumocystis carinii pneumonia ( PCP ) unless recover . Clinically significant cardiac disease , include history myocardial infarction arrhythmia . Concurrent neoplasms basal cell carcinoma skin . Known hypersensitivity polymycin B neomycin . Excluded patient : Active opportunistic infection require ongoing therapy . Excluded within 90 day study entry : Must therapy Pneumocystis carinii pneumonia ( PCP ) unless recover . Clinically significant cardiac disease , include history myocardial infarction arrhythmia . Concurrent neoplasms basal cell carcinoma skin . Known hypersensitivity polymycin B neomycin . Prior Medication : Excluded : Interferon . Zidovudine ( AZT ) . Excluded within 30 day study entry : Any biologic modifier , corticosteroid , cytotoxic chemotherapeutic agent . Other drug cause neutropenia significant nephrotoxicity . Rifampin rifampin derivative , systemic antiinfectives . Excluded within 90 day study entry : Other antiviral agent . A history Pneumocystis carinii pneumonia ( PCP ) complete treatment . Prior Treatment : Excluded within 30 day study entry : Radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Interferon Type I</keyword>
</DOC>